[1] Bahn R S.Graves' ophthalmopathy[J]. N Engl J Med,2010,362(8):726-738. [2] Bartalena L,Baldeschi L,Boboridis K,et al.The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the management of graves' Orbitopathy[J]. Eur Thyroid J,2016,5(1):9-26. [3] Mourits M P,Koornneef L,Wiersinga W M,et al.Clinical criteria for the assessment of disease activity in Graves'ophthalmopathy:a novel approach[J]. Br J Ophthalmol,1989,73(8):639-644. [4] 李眉,燕飞.医学影像学评估甲状腺相关性眼病活动度的价值[J].眼科,2018,27(5):321-324. [5] Kahaly G J.Recent developments in Graves' ophthalmopathy imaging[J]. J Endocrinol Invest,2004,27(3):254-258. [6] Dodds N I,Atcha A,Birchall D,et al.Use of high-resolution MRI of theoptic nerve in Graves' ophthalmopathy[J]. Br J Radiol,2009,82(979):541-544. [7] Bartley G B,Gorman C A.Diagnostic criteria for Graves'ophthalmopathy[J]. Am J Ophthalmol,1995,119(6):792-795. [8] Regensburg N I,Wiersinga W M,Berendschot T T,et al.Do subtypes of Graves' orbitopathy exist?[J]. Ophthalmology,2011,118(1):191-196. [9] 危昆桥,魏锐利,马晓晔,等.甲状腺相关眼病眼眶CT定量测量及亚型分析[J].中国实用眼科杂志,2014,32(2):161-165. [10] Galuska L,Leovey A,Szucs Farkas Z,et al.SPECT using 99mTc-DTPA forthe assessment of disease activity in Graves' ophthalmopathy:a comparison with the results from MRI[J]. Nucl Med Commun,2002,23(12):1211-1216. [11] 罗莎,王爽,李眉,等.99mTc-DTPA眼眶SPECT/CT评价甲状腺相关性眼病活动性[J].眼科,2018,27(5):344-348. [12] Eckstein A K,Plicht M, Lax H,et al.Thyrotropin receptor autoantibodies are Independent risk factors for graves'ophthalmopathy and help to predict severity and outcome of the disease[J].J Clin Endocrinol Metab,2006,91(9):3464-3470. [13] Lantz M,Planck T,Asman P,et al.Increased TRAb and/or low anti-TPOtiters at diagnosis of graves'disease are associated with an increased risk of developing ophthalmopathy after onset[J]. Exp Clin Endocrinol Diabetes,2014,122(2):113-117. [14] 王朝点,史育红,颜兵. TRAb水平测定在Graves眼病中的临床意义探讨[J].国际放射医学核医学杂志,2013,37(2):77-80. |